Vorasidenib inhibits both mtIDH1 and mtIDH2 at nanomolar concentrations80 and is currently under investigation for IDH1/2mt glioma.32 Its dual mtIDH1/2 inhibition will likely reduce the possibility for IDH1/2mt cells to escape mtIDH1/2 inhibition via isoform switching. Here, IDH1 is linked to central nervous system cancer.